12:00 AM
Mar 02, 2009
 |  BC Week In Review  |  Company News  |  Deals

e-Therapeutics Ltd., Khandelwal Laboratories deal

Khandelwal received exclusive rights to develop and market in India e-Therapeutics' ETX9101 for asthma, ETS6103 for severe major depressive disorder and ETX1153b for methicillin-resistant Staphylococcus aureus (MRSA) infection. The companies will share revenues 50:50 and...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >